pembrolizumab,IMM60
merck,portage
['melanoma', 'nsclc', 'pembro', 'sclc']
from 8am cdt, &amp; mark middleton will present results from a dose finding/randomised study of a novel agonist and pembrolizumab for advanced #melanoma &amp; metastatic #nsclc: #crukfunded #asco23 
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK